«Ozon Pharmaceutics» Breaks Records, Market in Motion: Ruble Fluctuates, VTB Shares Change Status: Investment Review

Key market news for today:

• MOEX Index rose by 1%, driven by a slight weakening of the ruble, which boosted trading activity on the exchange.
• Ruble exchange rate strengthened to 10.95 per yuan but then returned to 11. Today, currency rate stabilization is expected.
• Brent oil was trading around $95 per barrel in the morning, and experts forecast price stability at this level in the near term.
• OFZ yields for maturities over five years fell by an average of 5 basis points after successful Ministry of Finance auctions. Further bond price growth is expected.
• «Ozon Pharmaceutics» published IFRS reporting for 2025. The company showed 24% revenue growth due to increased sales and higher prices. EBITDA grew by 28%, reaching a margin of 38.5%. Net profit increased by 34%, with a margin of 19.5%. Debt burden decreased to 0.8 of EBITDA, though free cash flow remained negative. The Board of Directors of «Ozon Pharmaceutics» recommended paying **final dividends** of 0.27 ₽ per share for 2025, which together with interim payments will amount to about 20% of net profit.
• NOVATEK presented operational results for the first quarter of 2026, confirming stability in production and sales.
• VTB approved the conversion of preferred shares into ordinary ones, which may affect the bank's capital structure and liquidity.
• Analysts' opinion. Experts rate «Ozon Pharmaceutics»' report as strong and forecast 17% revenue growth for the company in 2026. The company itself targets a range of 15% to 25% growth, indicating positive expectations for the coming year, reports the «SberInvestments» channel.